Valuation: OpGen Inc

Market Cap 113M 98.4M 91.59M 84.15M 159M 10.82B 162M 1.08B 424M 5.39B 426M 417M 17.86B P/E 2024
0.26x
P/E 2025 6.86x
Enterprise Value 115M 99.54M 92.65M 85.13M 161M 10.95B 163M 1.09B 428M 5.45B 431M 421M 18.06B EV / Sales 2024
1.29x
EV / Sales 2025 5.39x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 50 2025-11-30
Chief Tech/Sci/R&D Officer 37 2025-03-31
Chief Operating Officer 54 2024-12-03
Director TitleAgeSince
Chairman 36 2024-08-01
Director/Board Member 39 2024-08-08
Director/Board Member 40 2024-08-08
Change 5-day change 1-year change 3-year change Capi.($)
+21.45%+1,817.73% - - 6.39M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average +0.80%+1.05%+59.43%+103.27% 27.82B
Weighted average by Cap. -1.60%+2.03%+76.87%+128.10%

Financials

2024 2025
Net sales 5.2M 4.51M 4.2M 3.85M 7.28M 496M 7.4M 49.41M 19.4M 247M 19.51M 19.08M 818M 30.2M 26.2M 24.38M 22.4M 42.33M 2.88B 43.01M 287M 113M 1.43B 113M 111M 4.75B
Net income 11.99M 10.4M 9.68M 8.9M 16.81M 1.14B 17.08M 114M 44.78M 570M 45.04M 44.05M 1.89B 23.62M 20.49M 19.07M 17.52M 33.11M 2.25B 33.64M 225M 88.19M 1.12B 88.7M 86.75M 3.72B
Net Debt 711K 617K 574K 527K 997K 67.82M 1.01M 6.76M 2.65M 33.78M 2.67M 2.61M 112M 1.32M 1.14M 1.06M 977K 1.85M 126M 1.88M 12.52M 4.92M 62.55M 4.94M 4.84M 207M
Logo OpGen Inc
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
Employees
-